Chimeric antigens for eliciting an immune response
AssigneePaladin Labs Inc.
InventorsRajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.
Claims33
A method of enhancing hepatitis B virus (HBV) protein antigen presentation by an antigen presenting cell, said method comprising administering to a subject a purified chimeric fusion protein antigen, wherein the chimeric fusion protein antigen comprises:
- an immune response domain comprising one or more immunogenic portions of a HBV surface protein;
- a target binding domain consisting of a hinge region, at least a portion of a CH1 region and a xenotypic Fc antibody fragment comprising at least a part of a CH2 and CH3 domain;
- wherein the immune response domain and target binding domain are linked by a peptide linkage;
- and
- wherein the chimeric antigen comprises non-mammalian glycosylation.
A method of activating an antigen presenting cell comprising contacting the antigen presenting cell with a purified chimeric fusion protein antigen, wherein the chimeric fusion protein antigen comprises:
- an immune response domain comprising one or more immunogenic portions of a hepatitis B virus (HBV) surface protein;
- a target binding domain consisting of a hinge region, at least a portion of a CH1 region and a xenotypic Fc antibody fragment comprising at least a part of a CH2 and CH3 domain;
- wherein the immune response domain and target binding domain are linked by peptide by a peptide linkage;
- and
- wherein the chimeric antigen comprises non-mammalian glycosylation.
A method of eliciting an immune response to a hepatitis B virus (HBV) surface protein antigen, said method comprising administering to a subject a purified chimeric fusion protein antigen, wherein the chimeric fusion protein antigen comprises:
- an immune response domain comprising one or more immunogenic portions of an HBV surface protein;
- a target binding domain consisting of a hinge region, at least a portion of a CH1 region and a xenotypic Fc antibody fragment comprising at least a part of a CH2 and CH3 domain;
- wherein the immune response domain and target binding domain are linked by a peptide linkage;
- and
- wherein the chimeric antigen comprises non-mammalian glycosylation.
A method for treating a subject with a hepatitis B virus infection comprising administering, to a subject with a hepatitis B virus (HBV) infection a purified chimeric fusion protein antigen, wherein the chimeric fusion protein antigen comprises:
- an immune response domain comprising one or more immunogenic portions of an HBV surface protein;
- a target binding domain consisting of a hinge region, at least a portion of a CH1 region and a xenotypic Fc antibody fragment comprising at least a part of a CH2 and CH3 domain;
- wherein the immune response domain and target binding domain are linked by peptide by a peptide linkage;
- and
- wherein the chimeric antigen comprises non-mammalian glycosylation.
A method of vaccinating a subject against a hepatitis B virus (HBV) infection comprising administering to the subject, a purified chimeric fusion protein antigen, wherein the chimeric fusion protein antigen comprises:
- an immune response domain comprising one or more immunogenic portions of an HBV surface protein;
- a target binding domain consisting of a hinge region, at least a portion of a CH1 region and a xenotypic Fc antibody fragment comprising at least a part of a CH2 and CH3 domain;
- wherein the immune response domain and target binding domain are linked by peptide by a peptide linkage;
- and
- wherein the chimeric antigen comprises non-mammalian glycosylation.
Dependencies are inferred from the claim text.